Novel Biotechnology develops the NBX Platform™, a plasmid DNA manufacturing system that significantly increases yield, speed, and quality compared to traditional methods. This technology addresses the DNA bottleneck in drug discovery, enabling faster development of genetic medicines such as cell and gene therapies and RNA therapeutics.
Funding
$366.8K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JCMOFounders
Product
Problem
Traditional plasmid DNA (pDNA) manufacturing methods, which rely on *E. coli*, suffer from limitations in yield, speed, and quality, creating a bottleneck in the development of genetic medicines. This bottleneck slows down drug discovery and hinders the progress of cell and gene therapies, RNA therapeutics, and nucleic acid vaccines.
Solution
Novel Biotechnology's NBX Platform™ overcomes the DNA bottleneck by providing a plasmid DNA manufacturing system that offers higher yield, faster growth, and improved quality compared to conventional *E. coli*-based methods. The NBX Platform™ is fully compatible with existing workflows and accelerates the production of high-quality pDNA, reducing development timelines and minimizing costly failures. By scaling quality pDNA, the platform enables the development of first-of-their-kind medicines and accelerates genetic medicines to the clinic.
Target Audience
The primary target audience includes biotech companies involved in synthetic biology, pharmaceutical drug development, gene and cell therapy, nucleic acid vaccines, and mRNA manufacturing and therapeutics.
Features
- Higher yield of plasmid DNA compared to traditional methods
- Faster growth rates, accelerating production timelines
- Improved DNA quality, reducing the risk of production failures
- Compatibility with existing laboratory workflows and equipment
- Capability to handle complex DNA designs and large plasmids (>100 kbp)
- NBx CyClone™ product (Early Access May ‘25) offers 3x faster workflows than E. coli and maintains sequence motifs E. coli can’t handle